NCT07374263 Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
| NCT ID | NCT07374263 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Joseph's Healthcare Hamilton |
| Condition | Acquired Long QT |
| Study Type | OBSERVATIONAL |
| Enrollment | 990,000 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2027-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence. The association between many commonly used medications listed as known QTPmeds and actual major adverse cardiac events (MACE) is weak. Meanwhile, QTPmeds-related warnings are ubiquitous in every healthcare setting, triggering 'hard stop' disruption millions of times per day to front line clinicians. Poor quality medication safety alerts are increasingly recognized as a source of inferior patient care and provider burnout which detracts from healthcare sustainability. In this study, anonymized hospital electronic medical record data from more than 990,000 adult patients across Ontario will be used to compare patients who experience MACE with those who do not, measuring their real-time exposure to QT-prolonging drugs. Additionally, machine-learning techniques will also be used to find which patient or treatment factors best predict risk. The objectives of this study are to 1) Investigate whether exposure to one or more 'Known' QTPmed is associated with an increased risk of MACE after adjusting for confounders; and 2) Identify predictors and their relative importance for QTPmeds-associated MACE. In summary, QT-prolonging medications have the potential to cause very serious adverse events, including death. However, it is not sufficiently clear which patients under which circumstances suffer events, or when is QT prolongation a useful surrogate marker for harm. Meanwhile, ubiquitous medication alerts related to QT-prolonging medications are at best imprecise and at worst, misleading, costly and potentially dangerous. Now that data resources are available with the data elements, structure and sample size required to rigorously assess this association, this study will address this question to improve patient safety, provider satisfaction and the cost-effectiveness of care.
Eligibility Criteria
Inclusion Criteria: * Adult patients 18 years of age or older * Admitted to St. Joseph's Healthcare Hamilton or GEMINI hospitals between December 2017 and March 2025 Exclusion Criteria: * Patients \<18 years old * Outpatient encounters